AFC Gamma, Inc. (AFCG) is a leading institutional lender to U.S. state-licensed operators within the medical cannabis industry. Its licensed operators grow, extract, manufacture, and distribute medical cannabis products throughout the U.S. The company holds a significant space within the medical cannabis industry, serving to fill the significant financing gap for licensed operators forced by federal regulations into mostly cash operations.
Founded in 2020 and headquartered in Florida, AFC Gamma is a real estate investment trust (REIT). The company prides itself on a strong leadership team with experience in finance, real estate, agronomy, and the cannabis industry. Their strategic lending approach aims to provide optimized capital solutions that meet the unique needs of each licensed operator they service, hence making them stand out from other financial service providers within the industry.
In terms of their financial offerings, AFCG provides bridge finance to assist with real estate acquisitions, refinancing, and growth capital. It aims to help its clients navigate their difficult circumstances, providing structured finance solutions that are tailor-made for different scenarios. These scenarios could range from construction and term loans to leasing property for medical cannabis operations.
Besides their lending services, AFCG also involves itself in acquiring, owning, and managing real estate properties meant for the cultivation and retail sale of medical cannabis. Its stringent investment strategy focuses on finding and investing in high-quality, well-located facilities that can be leased to experienced, state-licensed operators.
An essential aspect of AFC Gamma is its compliance with the rules and regulations that govern the medical cannabis industry. Given the nature of the cannabis industry in the U.S., all partners must adhere to state-specific regulations. While federal law technically bans the use of cannabis, AFCG operates within the parameters of states where medical cannabis is legalized.
AFC Gamma, Inc. has contributed greatly to the growth, development, and continued viability of the medical cannabis industry in the United States. Their unique and essential financial solutions provide the necessary lifeline for licensed operators within the industry, creating sustained growth and advancement in a rapidly developing medical sector. In a climate where traditional financial institutions tend to shy away, AFCG has emerged as a critical player, providing necessary financial solutions and real estate opportunities for those within the medical cannabis industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
AFC Gamma (AFCG) is expected to release its Q3 2026 earnings before market open on November 5th, with analysts forecasting EPS of $0.16 and revenue of $8.33 million. In the previous quarter, the company exceeded EPS estimates at $0.23 but missed revenue expectations. Despite a "Reduce" consensus rating from analysts, company insiders have significantly increased their holdings in the stock recently.
AFC Gamma Director Leonard Tannenbaum recently acquired 44,643 shares of the company's stock for over $162,000, increasing his total ownership to 7.11 million shares. Despite exceeding quarterly EPS estimates, the company missed revenue expectations and announced a $0.05 quarterly dividend. Analyst sentiment remains cautious, with a "Reduce" consensus rating for the stock.
AFC Gamma Director Leonard Tannenbaum recently purchased 40,081 shares of the company's stock for approximately $143,891, increasing his stake to 7.06 million shares. The company reported quarterly EPS of $0.23, surpassing estimates, and declared a quarterly dividend of $0.05 per share. Despite these positives, analysts maintain a "Reduce" rating on the stock.
AFC Gamma Director Leonard Tannenbaum recently purchased 10,673 shares of the company's stock for over $38,000, increasing his total holdings to more than 7 million shares. The company reported quarterly earnings that beat analyst estimates but revenue that fell short, and declared a dividend yielding 5.6%. Analysts currently maintain a "Reduce" rating on the stock.
AFC Gamma director Leonard Tannenbaum recently purchased 20,000 shares of the company's stock for $69,800, increasing his stake to over 7 million shares. Despite this insider buying, analysts have an average "Reduce" rating on the stock, with one Hold and one Sell rating. The company's latest quarterly earnings beat estimates, but revenue fell short of forecasts, and it declared a quarterly dividend of $0.05.
AFC Gamma (NASDAQ:AFCG) Director Leonard Tannenbaum recently purchased 3,471 shares of the company's stock for $12,113.79, increasing his total holdings to nearly 7 million shares. This transaction occurred on September 23rd, shortly after the company's latest quarterly results, which beat EPS estimates but missed revenue expectations. AFC Gamma also declared a quarterly dividend of $0.05 per share, while analysts maintain a "Reduce" consensus rating for the stock.
AFC Gamma (NASDAQ:AFCG) Director Leonard Tannenbaum recently purchased 23,072 shares of the company's stock for approximately $80,521, increasing his total holdings to over 6.9 million shares. Despite exceeding quarterly EPS estimates, the company's revenue fell short, and analysts currently maintain a "Reduce" rating on the stock. AFC Gamma has also declared a quarterly dividend of $0.05 per share, offering a 5.7% annualized yield.
AFC Gamma Inc. (NASDAQ:AFCG) has declared a quarterly dividend of $0.05 per share, payable on October 15th to shareholders of record as of September 30th. This dividend represents a 5.7% yield and is covered by the company's earnings, with a payout ratio of 17.1%. The company recently reported quarterly EPS of $0.23, surpassing analyst estimates, and insider activity shows significant buying by Director Leonard Tannenbaum.
AFC Gamma (NASDAQ:AFCG) Director Leonard Tannenbaum recently purchased 15,000 shares of the company's stock for $53,250, increasing his total stake to nearly 6.9 million shares. The company reported better-than-expected quarterly EPS of $0.23, although revenue missed estimates at $6.77 million. AFC Gamma also declared a quarterly dividend of $0.05 per share, representing an annualized yield of 5.7%, while analysts maintain a "Reduce" consensus rating on the stock.